<SEC-DOCUMENT>0001193125-12-300258.txt : 20120712
<SEC-HEADER>0001193125-12-300258.hdr.sgml : 20120712
<ACCEPTANCE-DATETIME>20120712061059
ACCESSION NUMBER:		0001193125-12-300258
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120710
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120712
DATE AS OF CHANGE:		20120712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AP PHARMA INC /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		12958519

	BUSINESS ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		STREET 2:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d377759d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM&nbsp;8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act
of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>July&nbsp;10, 2012 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>A.P. PHARMA,
INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-33221</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94-2875566</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>123 Saginaw Drive</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Redwood City, CA</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94063</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code:&nbsp;(650)&nbsp;366-2626 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General
Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01&nbsp;Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;10, 2012, A.P. Pharma, Inc. (the &#147;Company&#148;) announced that the United States Patent and Trademark Office (USPTO) has allowed three new patents covering the Company&#146;s lead
product candidate, APF530, which is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). The newly allowed patents, when issued, will extend the patent life around APF530 through 2024.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01&nbsp;Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit&nbsp;No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:72pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Document Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release issued on July&nbsp;10, 2012</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. PHARMA, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: July&nbsp;12, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John B. Whelan</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d377759dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%">


<IMG SRC="g377759image-2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For Immediate Release </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma Announces the Allowance of </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Three Patents Covering APF530 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#150; APF530 patent protection extended through 2024 &#150; </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">REDWOOD CITY, Calif. &#150; July&nbsp;10, 2012 &#150; <U>A.P. Pharma, Inc</U>. (OTCBB: APPA.OB), a specialty pharmaceutical company, announced today that the United States Patent and Trademark Office
(USPTO) has allowed three new patents covering the Company&#146;s lead product candidate, APF530, which is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). The newly allowed
patents, when issued, will extend the patent life around APF530 through 2024. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;The newly allowed patents are instrumental in bolstering
APF530&#146;s overall patent life and will extend the intellectual property protection surrounding the product through 2024,&#148; said John B. Whelan, A.P. Pharma&#146;s president and chief executive officer. &#147;A.P. Pharma continues to make
advancements related to APF530 beyond clinical and regulatory development, and the allowance of these patents provides added strength to the APF530 patent estate and will help support the product&#146;s longevity.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Patent Details </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent application number 13/279,949, entitled &#147;Process for Preparing a Semi-Solid Delivery Vehicle Comprising Granisetron,&#148; relates to
methods for preparing extended release formulations of granisetron. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent application number 13/279,938, entitled &#147;Methods of Treating Emesis Utilizing Semi-Solid Pharmaceutical Compositions Comprising
Granisetron,&#148; relates to methods for the treatment of emesis using extended release formulations of granisetron. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Patent application number 12/564,881, entitled &#147;Semi-Solid Delivery Vehicle and Pharmaceutical Compositions for Delivery of
Granisetron,&#148; relates to compositions for extended delivery of granisetron. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional information regarding these
patent applications can be found on the USPTO website. APF530 is already covered by multiple issued patents on the polymer technology and formulations that extend into 2021. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About APF530 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma&#146;s lead product, APF530, is in development for the prevention
of both acute-onset and delayed-onset chemotherapy-induced nausea and vomiting (CINV). APF530 contains the 5-HT3 antagonist, granisetron, formulated in the Company&#146;s proprietary </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- more -
</I></FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>A.P. Pharma Announces the Allowance of Three Patents Covering APF530</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> Page&nbsp;
 2
</FONT></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Biochronomer&#153; drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. Intravenous and oral formulations containing
granisetron are approved for the prevention of acute-onset CINV, but not delayed-onset CINV. Granisetron was selected because it is widely prescribed by physicians based on a well-established record of safety and efficacy. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About A.P. Pharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma is a
specialty pharmaceutical company developing products using its proprietary Biochronomer&#153; polymer-based drug delivery technology. The Company&#146;s primary focus is on its lead product, APF530, for the prevention of CINV. A.P. Pharma received a
Complete Response Letter on the APF530 NDA and is targeting the resubmission of the NDA in mid-2012. The Company has additional research and development programs that utilize its bioerodible, injectable and implantable delivery systems. For further
information, please visit the Company&#146;s web site at <U>www.appharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-looking Statements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This news release contains &#147;forward-looking statements&#148; as defined by the Private Securities Litigation Reform Act of 1995. These
forward-looking statements involve risks and uncertainties, including uncertainties associated with capital resources and liquidity, timely development and regulatory approval of product candidates, satisfactory completion of clinical studies,
progress in research and development programs, launch and acceptance of new products and other risks and uncertainties identified in the Company&#146;s filings with the Securities and Exchange Commission. We caution investors that forward-looking
statements reflect our analysis only on their stated date. We do not intend to update them except as required by law. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contacts
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Michael Rice </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office Phone: 646-597-6979 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Email: <U>mrice@lifesciadvisors.com</U> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">and </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma, Inc.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan, President and Chief Executive Officer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Office Phone: 650-366-2626 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>### </I></FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g377759image-2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g377759image-2.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`-P"O`P$1``(1`0,1`?_$`*8```$#!0$!`0``````
M```````("0H"!`4&!P$#"P$``0,%`0````````````````8'"`$"`P0%"1``
M``8!!`(!`P,#`@4%`````0(#!`4&!P`1$@@A"1,Q(A1!,A51819Q(X&1)!<*
MH;'!,R41``$"!0,"!0(#!@8#`0````$"`P`1!`4&(1(',4%182(3"'$R@2,4
MD:'!0E(5T>%B<C,6\+'$)?_:``P#`0`"$0,1`#\`G\:((-$$&B"$-=KO89UB
MZ=-U4LL9!9GMZR'RQ&,:LF%AR'+'$@&1`D"S5`\8U<;^'#TS=';SR$-+K$.-
M<OSIT-V"F/L3U?<FEH`=9JEVZ:3\X;_,N4,+P-L_WVJ!KM)4[<E/&8F))GW&
MNLHCL]AO_(2["6MZ\A^O.,*GBF&!8R;.;NZ1;W<UD1`=G*T<11E5HQ0"B&R1
M@=\#B`"8VI88K\5L?IZ=+^75;M34D?8SZ$),]3N&XJ';M$/LT^6.7N59I<*H
M&Z=I)^YT%Q:DD:33Z0D_MAMJS^SKV$W)^>1F>T.469^:ATVE6<0-3CD>?C@1
MC"P3=`2E`/H._P#KIXJ'A3BNWL!I%KIG5])NS63^,Q#.U'-'--U<+]375;;8
M$Y-$-@>.A2J<HIJ?L^[]4I\G*17:7*3U\B;G^);5X2V0K@B9@4,DXC)>$5;J
M%-ML(`)3"'@#!JEPX,XTN#'LJM=.T@@ZL@I6/,&9C!2<^\B6=1>;N=:NI21)
M+R@XA730C:F7[3$A7UF>Z0_9"X0N`^RT1"T_+%@,+2D7N`2/'U*^RJ22BQH"
M0B7:JBE;LSM%(QFI2J':O!*)$^*@<!B3R]\?5X52KR#%?<<LP,W$+!*VQH)S
M[CZ@$`]XEWPE\D&\YJ$8[ER6V+XX#[+B=&WI'H!.0(E+J9D=HD*)`7Y!$"[B
M"8%Y_P!/(")/[[F\ZC,VI"YE!!`,B/.)7J^_4:RZ^,7.LD$&B"#1!!H@@T00
M:((-$$&B"#1!!H@@T00:((-$$?)0-Q)X`2ARY!^O[1VX_P#S_;5BD-J4E2_O
M29I_C^Z`;IR'VGK&)DY6-BX]\_D72,;'1C9=X_?/%$VS)HS:IBNY7=.UE$T6
M[=%(!,<YS%*4-QW\:N"5O.AMEM3M4HA*4@$DJ.@&GGY0/E%&P:EUQ+=.@%2B
M2``D:DZ^0B+E[%/=]*.AGL2=)W@-V+1=U"6;/WPI++*G*;\5VVQ>P7YI'1((
M'3&7734+R*(H)#^_4P^)OCH:CV+]GR93&Y%+T*?#W//_`$=""#/L(9<P?(NJ
M135%KX]!+:5;'*H:A7]7M>0Z;YZ$'2(PD]-S5EFI*PV2<E;+8)9TJ\EI^<D'
M,I,R;Q8PG6</Y%XJLY<+&4$=^1M@^@``!L$Z;704=MH6Z*A;2W3-IVI2```!
MVD`(\\;Q<*VY7)VNKG5NU3BMRE*)))(F>I/[8LVJBI!5%-(RPF*4#!Q$XAN8
M`#]0\F^@"(@&LM44I2D^?C+M%UJ_4+4ZVRDK6M$NA.DQ/N/I.+\ZY0`4SM`Y
M"41`?D*'@-R\A`3;@4!#;?Z".M7:I1]R<=-;Z$L?H'6?S1YD?^2_A`#%<4_R
M#""!2"'(P[^!#P!1'<2[B'T^NCWU$["=3X106MQ+/ZM4DH3T)ZGMH(OX"7F(
M&:C+7!R*S">J[UE9H*23/\2K65@GJ4@Q<E,E]YB$6;!N`_4`V_77+O5/3UMG
MJ*)[:MEUI:3X:I,NL^ACL8XNI3=Z>O;4453*TN)/B$J$QI+L-(_2_P`56M:W
MXRQS<728D7M=#J%C<(EV`2+SU=CI14H@/D``[L0_OMKQ]O%.U;[O64*"-K-4
MM`GWVDB?[H]F;#5.UUBHJU0)4_1MK(`Z%20?XQT/Y2J`;81%,2"/`2^!X_4`
M'?Z@.N7[PZ@IG]8[.P%/M*0H'_&*71DRH%,8WQII%!0YAXB!$P((FW`VX>";
MCY#;QYU5LJ,Y#\V8T\R8I,-[DG_C"3,^``_RAG7H1[*;WW0[*Y[Q:WQI4J]B
MW#R,ZK'W1E,S#VP3A4KHO6JQ\[59-.)1_F&+%=TK\>W#8I2[AIXN2>*[9@>-
M6R_.U2W;K<&T*]DI"4I#B=ZB#,DR)D=(8OC/E^X<B9==<>9HTHL]K<<;]\$E
M2U(7M2`)2U`G.</%ICR6_P#K$!`A1Y*`)3%*'CA_03"(;[_^FF?!;!4V#HB0
MD.FHG/\`#I#X>HA*DI()&I/7Z?QBH52\E`'<1*`B(&'B(%^FX#L/+;Z:L4ZR
M3M#HW>'7]L7>I1DE!GX_X1XB<F^Q%%!X^/C,'V[_`*AOML(_V_35Z9[-GH!\
MM9?A%"ES=O5O_$1X=PFF90`*8P_J8"B.^X;[;;_<(``_3]`U@4A23L6I)</V
MS_C_``BNZ<UA*BGO+O\`2/FDLF781*8""8X_M,8I3>1V$?''8!V_7^FKA,F:
M%)2$_=Y_OBU(4/3L7N)F-.@C["NAR$F_W"7CML([!]?W`.P!L7]=@WU<5I^X
MK3[/A&7VW2=VT[O&*`4;[?%]W`"`7F("/VEV#<W@.`!M]1_]M6(<8"`AEQ`4
M!TG&-06!L6A6R?6*^92GX`(E`-A$3#O^P..W']`W-]?.LA5[B9H5(C]D7;5)
M2"1Z!WB@PD%0O(HBF.Y]Q*80,H(^#<?M,`[".WU^NK0I*-/<3[LN_AX1;)*_
M3L)$YSBY,9,-O!_/$?M*;<=]QV$NW+QQ\^-53[8)4"G?XQ5040.LI]H^3T_!
M,!$Y$TR@<ZISB`<4R$$QC<C&*4I2?4PCX``U?+U!<ID'0>,](L6%$2!`1(S)
MZ``1$5]FWL>CNTN:HGIQC?+#;%?6I"[-*ME_-+=F]DR6U\V>IH2_QMXM0KMS
MCBO."?"?XSD)(N2B=4WXR?F:?$?$M5B>./\`(%QH7*S*=N^EI%:>D@25TG[A
MZC^D`$3G$&N8^8J7,LGI>/;'7HI,;#P1550F29$A8$E#\L2D3K,S&A$6>&L&
M>EBW9LJO4^&4SYFN_P!KE5:DTS2A/2D129&T-H]RX5"%)$.&+5M%)G:G*DJ1
MHNV(<-@.8OW#LY#EOR$I+$]F]4FAMMOIY*-*4GW`DJ`&]*C,DS$S,3ZR[1=C
M^%?'RJO3.'4IN%?75!*15;ORBL)*CL4!("0/C*&FO8!UI@.I';+)V"JO.O;%
M6*V:!E:[(2AT3RZ459X9G,LXN640(FDL^BR.A3,MQ**Y2E.(`)AU(OB7-+CF
M^$4607)#;=8\'`L)!"9H<4B8!)T.T'K$5.:L,M^#\B5V/6U2W*)HM%)49JDM
MI"M2!(D3(_".'X)QNYRYG+$^)F1G)?\`N+D2HTYR+4YB."QTU,LF\FHFH38Z
M9DH\RH\@\E^NE!F]^_Z_BU9>U%*32TZU@GINE),_+=+2$S@5F-\S*BL*-Y34
MU"6R$F1*3J=9=A,](?\`^V?6STV])\W052RI"YNM,D>J1[Z8Q749N;GXV"0D
M7BZB5WMTNJ[:R!P<LR%*A'M5P$J29E/B,`^(?XCEG/G)-HJ+I:':--&'-J'/
M;*%'TB80)J!,YZD>741-C,,(^/'&=Z8H+VW7.UJD`K0'`M(GW6-H(&O6?G"8
MO:[T.P+UWH.#NR75US)IX=S*"$:M7I"6?33!FYDH(MFKLU!O)/E)-X^3BR*%
M5;*F,*:P%$-MQ`%UP%RCE&17FY8=F*VU7.@)`4$[53"MJDJU()'B`.O2&[^0
MG%N)8EC]#FF((=%KKI'8I>Y!W)W(($IRU!E/MUAH+'=&L&4+S2L>UIF=S-WJ
MT0-+A6B)#"HY>625:QAMB`.YDVI71U#F`?!2#J0N3U[5EL5;<5E*4-4RU:]!
MZ3UU\8COBEON5\O%#0L)!4Y4(:1+0J4I04K3N`V5?26L2S_;5W!SQTSCNI&"
M.L=J_P`=NUB@ACY%)M#0<\_F(NOMH&D52'00FV;Q%%23FC*`18A2FYD`!';<
M!@9PG@F/\@O7S*<I;6NTMJ6N:3MD[OW*UUT""=/+K'H5S=R-D/&[5@Q3$5MB
M\/)0B2P5;F@CV^@(U+@&OGTA,/;;(_NKZX4.'[39)R_3*W32O:_'2.-J(2%D
MVM.>RQ2HQK>W1SZN#_.(O7903>';NMR*J;$X@`;*_";'P/F5_7BEK9J??(5[
M;BU??M'JVJ*-):D0AL[O?/V$VE&<WVI:%K24%;38T1,C;N&[U!1(!Z=>ND.]
MUON@OD/U?3/<249-X2Q#@:Y3<S',C&1CFUUB6DI5'"<:93[BM'5A1!1MY$0!
M0H;CIC:O!E6SF%C"D!2T-W%.P=5%G=N&[34A&IT[0_\`39\B[<./YRYL0XY;
MEE?4)#FW:=HG,#=H-3$>?U988]BEJPOE>=ZFV"@X9K5TL2+>RYMN!P<6::?T
M^/556J--0_C9@K..;OI-15T],AR,L/`#E`H[REYFO?%5MR*CH,L;J:ZNH6TI
M;IDJ`:"7`#-8VF9E+:F8Z1$7@:Q\L5^*U]SPUVGHK9<7ENJJ7$E3NY"E`A!W
M)`!,PHF>L.6>D/N5V:SY=>P>*L^7I[D]ICF+@I:%MDLBR7E&<HZG9"#DH@9:
M/:,`DHU\5F#AJ*J8J%*41W$HZ:3Y`X!BF-4-LR#&FQ3&O0"6=)!)3NG+0C;H
M#YF'J^-V>YKE-RO%CRITU(H5Z.GJ5)4$$`])*F5`>'2<*,[<USVD9CSS-8]P
MA>J+UHZUP,#&R[?-"+E%_8K*Z5*)7T>\%RU<OXZ4:KD,`-FQ$$"-^*IW!A'B
M"+PBIX@LF,FZWMFINN6EV7Z9L`-@`ZST5.8EKWG(0M<[MW,&2Y)_:K!4TUFQ
M9*)_J5$^Z52[:I`UF)>4X19Z[NTW<&L>Q*S=+,TY]#L;3F,?<4%K495G+(-G
M]<A&\_'S5?GF[-!Z5LL"XM'39<ZQ/E'[1*)0W<KD_$<+KN+:;D3'[:;16OO`
M!@Z>D[A(IDF9,I@^$-?Q7G6<T?*M3QKD=R%VI66R?>&LR)&8()&U,]JO]7@8
M]]K_`'P[-8C[QXEPOURM5N^"'K%0EK!C6G)M%7.0K99YY9U%UEZ86+M\0KZ*
M8E34!(R8_"L;R`#R#'PWQKB]]XXK[]FC:&V%._EU"B`IM"?2J1.@DK2#FSE'
M+\?Y.M^.X:I]UU+0"F$`E#CBQN2%`=1MF3WT\HZM'7?V`=<.F7=OM!W&OTA#
MY2LT%")8.J$?,1#N,QJZE4E(]H2/A(Y`\=!2C::FR[)G4=*F2;A\BAS;B'#<
MLW'67\CV/%,&82;0TX4ON+!F^$IW$DR$R=I$]09Z:0JO[UR/B/&=\R[/*AUF
M[NM!3#:5#:SN4$@`2F-2#(ZB4NHA%F"6GMM[2]09_+ZO;M3'>(JPRO5L86>=
M?JER%DT*XDX-(MAEX2/(Z@:S'+12C=KL9,IE.1N!P$!!?Y*OA##L^8L;=G-7
M<''4M.-D@M-[CM!VE.J@3,D&<A+PAL,6:Y\S;CM^\*OJ:6W-H6XT[(^ZZ$ZR
MW;I!)`D)CO.?6/KT&R9[6>[V';!CC'78:(IM%I\\*5ESM=D5IC):2LG&H/6F
M.85ZW26<.TFZ:GY"CDQ2N$"GX"L(;:NY1Q_ACC/(6*^LMRJBL>294J%!*)`_
M<4E)`[:$ZC41FXMN_-?)F)KL]%=4L,LJ4'*M:"7`1IL"MXUZ@D#0CI'9/2GG
MCLY;.UW8K!V4\R6S+U(H-7E%W,G89=>=;-+A`7A&N-Y.`D'@"_;Q\XV(ZW;F
M,8@_&&X<@$1X7/>-8;08-:\EL5&U176N]E7MH`2D-K;*E`IZ[@=NL^OA'9^/
M.6YG7Y[=,7OU<[7VNA0M)<6=TWD+"9I/3:?492\-87SWBQ9[!<QYA0J6.NP5
M-ZN]2$:NVD)3*$1+I1UX<6`QQ0DH:;*__$<JKF-L=H#5VT:$;@)E5#*?8#7<
M>W_C?';4NLN]H?O.3^Z4!B6YK8>BP`E4E)D`?'<=(>/D6R<E9%=$T=GNC%GQ
MH,A7O@R<"Q*:%`D;DJF2/ME(:PT=UYR%V,IW>3*_1YSWKE<G8PN6&<P0;C,J
M]A"9@*G(N\03<O#7Z)D7<TY_@9?'DD8CIRJWDR("*!N2A?W%?/+;3B%7QW;>
M1&<;115S5SIR:39)3R0\"6R-HF'0G:!+HKI$>\6R3,J3D^X<;NY&*NWNVNHE
M5=4LN%HA+@]<A[95N5,_R]0(=&]X7=*1ZY==X[$]"?N([)^?SR,`219K`VD:
MYCIFFDG<IADL4WS-W\B5VE'-U"@/$7"AP\D#35_'G`$9?EW]VKV@Y:+8I*E)
M5T6XK_C_`-P29*4/I#K?)ODIW"<.1:+<XIN[W2:04]4M)^_7LI0FE)^L,0>L
M'H3C[L35\R=C>Q+N85P)UY9/EG58KIUF4Q>92)KBEJF(UU(MO^K:P</$&3,H
M1#@LX77`O,I-]20YFY.N^+W"BP;$BAJ^UZD)#RCM2V%K]M(2.RIR&XF4NVD1
MNX1XOH,KH*O.<RW+L]L2M8:0)K<VM^ZH+5_1*9*93W&<]8=-]5W9ZA]A^QLO
M5,"=+<-X)P/C^FSDT>_Q]=&:R(,@JY:1M<;/;R9HBS;S,B5=5RY0`RRHH@.Y
MQV$PL!S1AURQO&&:_)LA?K\BJ*E*%,[Y)`[D`*.Y,P!.4ID1(#AK-+5EF4/4
MF,V.CH,?IJ<J#R1-<]9`G:-JC,G;.<AK#(79#'^=.]/>OM5.83Q]8LIR<7D*
M;^1C7Q8G7C:?6I$M*A7"IG[UD@#=4\,4I`*<P@/Z;>=2CP:\X_Q=QK:6<EJ$
MT[2F#MG+<HN%3F@T_JG$1,\L&1\L\IW>JQ1@U6U^14-$@-`-&9UE(IE'9_3A
M@V8F?9/4XBW1*L>]PBQR!:['&.#MU5(NQUAJ>KM6;H[=5=$%V,])[CQ,8.27
MUUQ?D5E%$>)7$4JBINZ%IM!E*:20[/R]*857QIPVN1S$/[@A(<H&W'%`&<E)
MW-'M_5&@^P"OY3[/^SG--"JM;GG=QM&3&>+*M%.HE\BHVAJZT80+*664713(
MA7@:)'?*.3"#<R*@B4X[@`V\47:QX-PU35M34,)--2N/+DL&:MRU)\-9$"7C
M&MRG;KUF/-]9;:-JH6]5/-L!"D%)2C<A)(ZS3L!,_'3SAT+VP4.VY%8=.?6M
MUU@7F2<B8OQ\ED"SU^*=L&ZR$;5ZBVJ,,Y<N9-TT:(B^%1T\$IU0,"?$=ON+
MIH.#[G:[177SE[)W4TUHK:@AHJZK6M>XA`_FT/4'J##X<[6JMOS5AX;QUI=3
M<*6F"W0G4(2VT4)WG^7U`=1T,:KZ9/7/D"L=B+MF+/U14KSSKL^=TVMUYZLP
M?"KE.6BF[N1E`79.7;)P2HUZ5(4JB9C@5X[X[@=(=M_Y!\OV^[XZQ9L6=4[3
M5Z-[A`E^4#T.LP5$3EX`^,:GQQX=N5JR!=URMD-U%I<4A"9SF^HF2AI)24M+
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M/6D(WIVS4)@$F0E*-?[ZUV4Z9>EG$/7:061:6^W.J!2+4BF8$@4?/W3_`"9=
MFA0^ADFJK$43CX`1+^F^LW&EP&<_(FHRM$ETC"WE))T)9*2A!EX@$:?76-'E
M:W/8%\>*;$!Z:NI2TTK7HL'>X/.>TCS,O&%@=8Q1ZC^F2/MRJ)FDQ$]>+ME5
M50I.)CSV04)66C5^)=A%?E.M0V_00VWTA,N=>S?G9;:4A2#=$MI/6:65!)F.
MWI2?PAQL*ID<?<`I6N:6V[:MPCN"^"M('XK$_.$$>G6>9=8?7WV_[DS,6:6>
M-IAT+9F?F4\J7'U;9-6\8"R6Z@(/+;8#D.</``41';;<'.Y[IADO)EGP9"BE
M#324*(Z`.$*GX:)29><A#:\"W!S'.+[QG[B-7E[T@B1):3LD>_W]?$3,<<Z^
MU)#V&X]R3W$]B7<ZPU/%55M,S"QV':;=VM-@8UI#-4G[AJG&INC*IM%"OP09
M))-5G[L""H90>6N]E-6[Q9>J7!.+K*R[>%,H]VK4T7%+W"?W"73^:9](A)8Q
M1CE>QU7(W*U^>I[$V^KVJ5MX-I3M)`FDS)G+TR'JZZ1EO0-C>MV#M9V.RU6V
M"R--Q]55:UC]%VX5>N(^+O\`:5GD2DNX6`JRSP:G!D!0ZH%.(JCN&^N?\G+T
M^SBUEM%Q4E-R6TA;J$_:%)2`H@_[E::=(V/BS8T5.<W[(*9*EVM#BT,+5]VQ
MP[TB7;TCU:]8W#JPF;LO[W,W91.J+R#Q&ZR([8&%/Y4&Y*>Q:8IKAD3`/T*X
M67.38-A$!$-5S`.8?\<J"SA14Y<%-S_VO3>('AK+QC?PY1S?Y(U]X<44-6[W
M-J`G3>Q^0"3/68)/02Z:PJS_`,A?)HUKJCCS&3;Y?R,D93;23Q-'9,3P](B7
MDDK]@F,)BJS#YGN`>!V\B&D1\7;8Q5YA4W9U&EMI%$$C^<G;,>)VA7[867RP
MN+@P>GLON+)K:I!6$C4M@$2_!:D1L/98X]1?2#%TR.,+*<D,+X]QT(I\$5/Y
MS*"C-S/&+N(<CD))/!_OMOKG8FT,NY]55K!=9%<^N77TI*BD_@9?2-_+B<%^
M-R:9O>V\+?3HZ2)6H(W:>)UG%MZOFY.LOJ.M>;)!(C60G(7,>9G@\!3V*R;2
M$)7D@W#=0XMX!#AL([@8-OKK/S`L9=SFBAI$*(;=8IY?ZT*`69>$@3/N!%G#
M%,YB/!"[C7+":AU%34*/31W<I`'>?J`EV42)Z0DGTE.$L)=3^[W<NPQ*DK)1
M(2"X(@(D4E_\"K#VX2[<%=C?"5_89@I3J;>``1TN_D2A%YRRP8$P0E+#82LC
M^EPHV2'DA)E"%^-[:,=PB_9\^A2WEJG(B9WM)4')]Y^Y^[6$]]=T\0=\F&9>
MV'LV[5S;2HTBQH-83!\5<U:LQ:L'<4E*E/$UY@H>6<P1/R@:M$HYL9TY.F91
M5?<>(*#,F;WQG446'<965LUCC$U5I05+44[0H&0`!F9J*E&4@`#"8Q.OQWDI
MBMS3E:\NMVI*TENA*O;V%04H2!))1(22`D`SG,1S[UN4G"5LS'W\S"K3UFW6
MW%/5[L"^953:2.^+C&]14NR_BDW`K?RW\D\QO%/B&'Y/R"F<_NY?3N<N7C(Z
M+'L7QU;D\PK+E1+WZ:/M.(T\/^52>VOA'+X>M^,5=QRJ]H1MQ&CMM<"D@E1I
M76UJF#.>K*5:=O'O',?=)EJ1RUWZR=$@[4=0V&65:QK!-@4Y-FR;*(:3MA.D
M0-RD57L<PL"@@`<A3`!_:&E=\<+&U8^,J2K3(.W!2W5D]2=Q;`^@"!*$;\D;
MV]E7)M70)W'^TE"$I_EV;$KG]2M2M8T/I)[-\Q](:_?:%4*=1LD8\OTH6;DJ
MM>$Y)((Z;/%(1$@Y8.8I4IGC.7CVR23AJX(9,W`!`0W$!W.2^#[1R-<&+Q4U
M#M+7,)EO0`3($F<B1(CJ#VC4XVYRO/'K3]EH*=FKH:E846W)I`5M"2#*9(,B
M".X,H[U7/>3VDH<K8$JKBOKW5Z5+,BQT/C:N41[5ZO5E1,J9W+LG$*[;R,G,
MNR+%*95T84@`H`5(!W,*7J/B]A=;3LIJ:NX/53:@LN+6%;I>1!"1WD.\=EOY
M6YI;;E44K-!;&*98*/;2@HD2-"2#K^(Z0E+IM[!<M]*I[+%EQI!8ZLD[EI1J
MXL$S>&DV^<-OQ7K^3,WBE8V58`1%60E3JF%0#&.9(HB7QMI;<B</V#D6AH*6
MY.OH8H4)0A+<I$)T!/GI(?7O"7XQY;O>"76YU-N31ERN67%%<Y`J]1"3,:`F
M9ZSEVAVOT=(J1;7O9W"MP_(M!5IZ@O/*E$2GE'#>>RG<3HN%0,8I#.5&A0#F
M(B40`WG3!?(XH6_CG'U%I3`HW3Z@`^RCZZ:F)"_'L*8_[+GU61N2TH!?8E0_
M4J(/8!1VCRA(L-[W^X3*K+Q`UC"<M<CLETFF7Y*CNU;RC$N3JJ)-EV;.4;03
MYZR;J%*54R9$A%,ICHG\[KYKXQX:_P"RXY4UYI%,H4M@+`;)($]93D?Z1XZ&
M&L3\J\II%/4RF*)5S0ZL-U7M3<4W,GL1Z@F<E$D3$RD](RGJ/E>XV:>[]PS9
M3%(FSS%B:KM,YYMRK#/YUE7*Q)R$;(O(^!1C9&(:&N<R@S2:Q[$G_3MFVXB0
MB9?.CS]0<=8_Q]2XQ5I]DM2-)3M$)FH3'JT/I$R2?&6LXZ?QWK^1<EY'K,CI
MB734*/ZE]Y)5M:4`I.TS'K(V@#PUB:4@SBH1D_=)(MF2'-W,2!T$R-R+K"8R
M\@^<@0-C+N#%,=0PB(F-Y$1VU`[\YQ24@DB00!X>`$>B3BZ:F0I9"0E(*UD:
M3(&I/G]8AX=*^M.,/:)W6[QW#+R<W(495[;)^(DZ].GBIB(G+#?7$33'T:_0
M(JF15G6H`RB1%2*HB&X"0=_$W\[RZY\1<=XY;L>4VBX**%N(4-R5M%HK.\3G
M+W"!V/G$#<!PRR<P<C7^X9"AQRA5O*'`9*0M+WM)"#+3\M.X=?I#XO5OT]=2
M>KM\8Y08,+GE3(<(H=>MV#*4TSF&U;7$@D+)1$*SCF,8293((@1XN59=+<?C
M$@B.\?LRYSS7-Z#^V53E+2T`!W)IT%&[R6=Q,OI+3K$B\2X#P#"KI_>*!%56
M702VJJ%^X$$:S1Z1(S\9ZPHCN3T9PQWGA*57<TR%\9Q-$E9*8B6=+LZ-=*M(
M2K)..<*R0JQLA^:4C(IB);<.'RG'SOX1N"Y_>\"KG;E9C3J6\V6R5)*M#]"-
M85V=<<6'DFD9H[Z:A"J9T.I""!ZAIK,'26D=(R_U?QKFWKTYZRVA6R1N,'5=
MKE4<H5B9_@Y@8"J#'?QK%*7*S<BFDH$6D5<`3_W2@(>-]:%GRZ[67)?^RTQ;
M5>O=<=!(F)K*B3*?GXZ1T;[AEGR#%EXC<O>1:"RVT=JI':@``3EY"-4Q?TFP
M!C#K%)]182`EYS#$W'6:*GHZT3*LG+S#>V.W#Z94>3B"#%=5T==<134(0IT@
M(38?MWUEN.=9!>\G_P"WUC@3D"%@I(T'IZ"1GI*-&Q\?8U8<2.$T+2U8^I*@
MH*,R0KJ9@=9^$(;I7HBZ%U.=/,RD+DV]-D/E-'P5VR*X>0+'FW5;MUE&D;'1
MBLDY:)*`*1W2BW$Q2F$!$-.7<_D?R1<Z9%&%T5-5MD'<TW^8LC^HJ41)7>0[
MPW-!\:.+Z)2W:D5E32J!DV\Y-M,^D@D)^WM/PUA;W4OH_@+I/!7:$PA'VADT
MR#)1\O8E;'97-G>*+QS)1DQ!H[<((*-6Z+=8P`4-PW'?3?YCR%DF?OL5F3%C
M]6RDI2$B0UD3/4SG+R^D./AG'N-\?4;U-CB7A3/D%14K<=!),B`)`#0>48?K
M#Z^NN/4B\9'R7B2,MB=NRL4P6^7M5L?691T"LZ[L1P9$>$3(P^23>G,<$P`#
M`!0$/&XY<FY%R;-+526>\K;-!1)2EM*$R`"$[!/4SD!UT[QBQ;CG&,+N=7>[
M.VL5]:M:G%*5,DN**SV'4F+WM;T,Z[]RI?'\QG:'M$\?''\A_C#&'M\K78LI
MY1Y'/WJD@RC3$2D%%58I$O\`N>!3`2CX$=8<6Y!R;"&*BGQTH2BK]+A*9G;Y
M&?2,F8<<XSGC]*_D"7%&E7N0$JD"1J-PD9B8G^$;7V8ZB84[9XTA<1YAC+$_
MI$%.Q4ZPB:]8Y&K&"2@V#J-B_P`AW%F(NLV9MG)A(F8>`G*4VVX:U<7S"_85
M>%9!85(3<EID5*&Z4^ND;&7X/C^=69&/7]#IM((DE*ML]LY`F1TC)R/5+#,A
MUK'J,O"R[7"?^%M*'_#L+#),I;_'6QT5/Q!L""A)0%W)TMU5N?-3D;?ZCJUK
M+[Z,H5F(>2K(E/EXDB?K5.9E^,958?81BR<,]DIQ]+`9"0==B92$Y==.L6F%
M.HF!^ON&)/KOCZHJ_P#:NP*612>@+#)O;`>8&VE.2=+*/I$ZKEVF\1-\8`8W
MV$``+MMJN09ID&1WL93<WIWM)1)0$I!'VR':4HMQW"<?Q6Q'&;8S_P#CN%94
ME1W3*S-<SI/<3"-ZGZ3?7=2[8E<$\0RME6;N?FCH.X76QV6KQ0F,HJ@1K!O7
M0-U6[4QMTB+BL!!`!#R`#I;UO.7)MPI4L.5X;4@:+2D!1\9DSZ]3(#6$&S\?
MN+V:]58JW%Y2M/;4HE"?"20!T&@F3H84+AOUV=2L"U;,U)QECQY"5S/E9D*I
MDYBZLUAEB3=>DXV6AGK!HK)OW)XE%6/G7"8`U^+B!@$-N(:3-[Y)S'(JJBO-
MVJR]6V]U+C"Y`%M:%)4E6@UVJ0#KX0K;)QIA./6^ML=HH&V:"X-+;?0)R<;6
ME2%I/D4J4/QB&S[<\>2V..__`&';2J"Z*=UM$9DJ"<G()$)"OVVOQ`-G"!A*
M`*@WE&;EN<0W`ATQ`=AVW]"OCO>:*X<:4%,RH%ZD:+2QW2H+43/]HCS:^3%H
MKK=R=7^ZE0:J70\V=0%)+:4Z>)FD_A#:P[@(@/(!#P8!`Q1`0^I1`0`=P'3\
M@A0F.D1T4%)5(G6/-Q'ZB(_ZB(ZK%OGWC(@J*;5`"+`;[3\D=P+PW4,`<C^>
M(&`?Z?KKF.E!J"#($']ND*.GJW*:B9;965)<GN3V3ZB-3YC_`-QTBLY;R]3J
ME8\>5;)5YJ]`LZ;E>RU.$M$E#UB7)(MT&<FI.1C91-!XBX9HE24*;83`4-OK
MI+7/%L9N5>U=[G2,.U[9]#BD@K2H="@G4'OU_?"SMU[RNBIJC';%4U#-N=0%
M+0E92DI41N"Q(A2>HEH?.'*.@_J(SQV[?0ETO"$EB+`*:B*ZELG6:[2UW%@`
ME%5K0(1R4BQVZI=B_P`DZX-TP\I@J;<-,]R=S[CV%-+L]GVU]^"2DA*@4MJE
M(%9$_M,IIT/;M#S<3_'/+<FJ$7B\K_26#<"%+0=[B29D(!,ANUDK4'K+M$TO
M`/7_`!=UGQQ"8HQ!56%3IL&B`)-FH`H^DY!387<S-R!R`ZEYJ04#FNZ7,=50
MP_4"@`!Y\9#DE\RN].WB].%Q]9.O8>`2.B4@:`#\8]%\=QNSXK:&[3:$!#"/
M(3)[DGN2?\HZ^Y:).T7C9RDFX:NTU$%VRI`42705;_$JBJ0VY3IJD$2B`[@(
M#KB)*PM*VEE*DF?TUF/\8[*FTK0M#B04*$I>(E(B.:8SPQB;$9Y8N+\8T7')
M9OX#S`4VIPE9-+*-C*"V/(##,F8//QA7/P^3D).9MA\CKIUMUNMRVBX5"GFT
M#TS),O&4SI',M=EM-I"U6VF2PMP^HI$MWU_'6.LZT(ZT&B"#1!!H@@T00:((
M-$$&B"#1!!H@@T00:((-$$,K^W#K!U#[(UZLQ^4NQ6&.NG82MP\F^QG9LC9`
MI=7<3-<5=?\`Z4)/0D_.P\G,4UU*%*!G"`'%DY^XG(1$@OIPKFN?X=7..8Q:
M:Z[65X@/H9IW7MA$B%!3:%!!(T,^HE$>N>L)X^S.@:;R>[T%HOK*2:=;]0RR
M5S!T*75I*A/6:>FO8Q#LR=U[GL733J+>7_!=U8H'53:V'%6>L0Y!BY3BH($7
M10C+DA,,$E""`@#AJ0P>=]M>@-@SFIO5(''+9=:.I'5+]%4H`TU`*FAN_`1Y
MSWG`*&TURVG;K:JBFVG:NGKZ1XDCH2D.B4_`JCES:FR3QPFU;O*\"JIN)#/+
MMCV.;`(_3Y7CZWMVJ)=_J8YR@&NLYDK[0]5+6J_VTE0?_2(X*,6H7!I<*8?5
MVE'_`-1A;&#>ACC)[AFXN_:GI7@R"%5,5W]X[0X@FK"4`.'(6M4J]KD?E.)0
M'B5=TAYVW_KINLEY5J;0MPVO'L@N%>!+:BWU2`=.H46B)#RZPZ>(\0V6\,)7
M=LFQZ@I5J!W+N%(IP25T+(>&TF6DUGJ#ITB05TYZ5^H3`,S!35C[3]<.QF7C
M.6A8J1O&;L1N8AK-`8H(%J>.6EK<L#/#+C_M'<?FN.6PE$HZBKR!GO.F5-*#
MMHO%KLPW>E%)4MJ*)2DXLM@$2UT"=8EUQOQUP%B;X53WJSW6^F4U+KJ5P;I@
M@MMI<)2>P$SII$AANE&_`A^(=M^+\3<6WXZB0M_Q^)1;`A\>Z?XXEVX`7[=O
MVZC*L.>XI+F[]1,[B9[I]YSUGXS_`!B52?;+"/;E^ETVREL\MLM/V1DM8Y>9
MC)'FP;_7S^OT_I^O_#0`C<92W=_\XKK**2@3D(E$.6WG80WVW_Y_754@!,D]
I(J2J6LY17JL6P:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T01__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
